5 Most-Read Articles From Our 2020 Publication
The most popular article from the Managed Healthcare Executive® print publication was a pre-pandemic story about the top 6 challenges facing healthcare executives.
Of course COVID-19 garnered most of the headlines in 2020. But the best-read stories from our print publication (which are subsequently posted on the website) covered a range of topics, from drugs in the pipeline to pulse oximeters to the top challenges for healthcare executives.
5. The Most Valuable Pipeline Drugs for 2020
Our predictions at the beginning of 2020 about the drugs headed for approval or sale. Reyvow (Lasmiditan), Adakveo (crizanlizumab-tmca) and Givlaari (givosiran) were on this pre-pandemic list.
4. At-Home Pulse Oximeters: The ‘It’ Gadget of the COVID-19 Outbreak
At-home pulse oximeter purchases have spiked 500% in the months after COVID-19 pandemic hit the United States because the disease lowers oxygen levels. The American Lung Association sounded a cautious note, advising against buying the device unnecessarily.
3. Five Healthcare Industry Changes to Watch in 2020
The 2020 trends we looked at included a shift from hospital to ambulatory settings, consolidation across the sector and effort to protect data privacy.
2. Top Pharmacy Regulations for 2020: What Pharmacists Should Know
Our story looked at limits on opioids, provisions in the Drug Supply Chain Security Act and pharmacists prescribing hormonal contraceptives.
1. Top 6 Challenges Healthcare Executives Will Face in 2020
COVID-19 overwhelmed every other challenges healthcare executives had in 2020. Our story in early January identified complying with new government regulations, a shift to value-based care and using big data as the hills that executives would be climbing in 2020.
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
FDA Clears Phase 2 Trial of Cannabis in PTSD
November 20th 2024After a three-year negotiation, the FDA has dropped its objection to allowing patients to self-titrate dosing of smoked cannabis. But regulators want to see additional information about the device that will be used for inhalation.
Read More
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
